Ergoteles’s GSK GSK Stock Holding History

Ergoteles’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,617	Closed	-$443K	–	1444
2022 Q4	$443K	Sell	12,617 -41,051	-76%	-$1.37M	0.02%	753
2022 Q3	$1.58M	Sell	53,668 -15,055	-22%	-$571K	0.06%	341
2022 Q2	$3.74M	Buy	+68,723	New	+$3.79M	0.11%	191
2022 Q1	–	Sell	-10,655	Closed	-$587K	–	1380
2021 Q4	$587K	Buy	10,655 +5,760	+118%	+$300K	0.02%	582
2021 Q3	$234K	Buy	+4,895	New	+$246K	0.01%	908

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ergoteles's GSK Position: Q1 2023 in Review

Ergoteles sold out of GSK (GSK) in Q1 2023, closing a stake of 12,617 shares — an estimated $443K sold.

Ergoteles first reported a position in GSK in Q3 2021 and held it in 5 quarters. The position peaked at $3.74M in Q2 2022. 809 funds tracked by Wall St. Rank hold GSK as of Q1 2023.

Ergoteles reported no remaining GSK position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 12,617 GSK shares in Q1 2023, an estimated $443K.
Ergoteles first reported a position in GSK in Q3 2021 and held it in 5 quarters.
Ergoteles's GSK position peaked at $3.74M in Q2 2022.
809 funds tracked by Wall St. Rank held GSK as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.